Cart
sales@molnova.com
NSC 207895
CAS No. 58131-57-0
NSC 207895( —— )
Catalog No. M17547 CAS No. 58131-57-0
NSC 207895 suppresses MDMX with IC50 of 2.5 μM, leading to enhanced p53 stabilization/activation and DNA damage, and also regulates MDM2, an E3 ligase.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 110 | In Stock |
|
| 2MG | 70 | In Stock |
|
| 5MG | 116 | In Stock |
|
| 10MG | 187 | In Stock |
|
| 25MG | 432 | In Stock |
|
| 50MG | 625 | In Stock |
|
| 100MG | 889 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 1786 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameNSC 207895
-
NoteResearch use only, not for human use.
-
Brief DescriptionNSC 207895 suppresses MDMX with IC50 of 2.5 μM, leading to enhanced p53 stabilization/activation and DNA damage, and also regulates MDM2, an E3 ligase.
-
DescriptionNSC 207895 suppresses MDMX with IC50 of 2.5 μM, leading to enhanced p53 stabilization/activation and DNA damage, and also regulates MDM2, an E3 ligase.
-
In VitroWestern Blot Analysis Cell Line:RAW 264.7 cells.Concentration:0.5 μM.Incubation Time:30 min (stimulated with LPS (100 ng/ml) for 6 h).Result:Upregulated p53 protein levels.
-
In Vivo——
-
Synonyms——
-
PathwayMetabolic Enzyme/Protease
-
TargetP450
-
Recptorp53 , MDMX
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number58131-57-0
-
Formula Weight279.25
-
Molecular FormulaC11H13N5O4
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 31.25 mg/mL (111.91 mM)
-
SMILESCN1CCN(CC1)C2=CC=C(C3=NO[N+](=C23)[O-])[N+](=O)[O-]
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Wang H, et al. Mol Cancer Ther, 2011, 10(1), 69-79.
molnova catalog
related products
-
(R)-Etomoxir sodium ...
(R)-Etomoxir sodium salt is R-form of Etomoxir. Etomoxir is a potent inhibitor of carnitine palmitoyltransferase-I (CPT-1).
-
Rhodionin
Rhodionin and rhodionin can inhibit cytochrome P450 2D6 non-competitively with high specificity which could have implications for interactions with co-administered drugs; they can significantly suppress the elevation of the postprandial blood triglyceride level suggests that they may be to the treatment of lifestyle-related diseases such as hyperlipidemia and exogeneous obesity and to health foods.
-
Opevesostat
Opevesostat (ODM-208) is an inhibitor of lyase (CYP11A1) (the enzyme cleavage cholesterol side chain).
